Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics, Inc.

An update from Sera Prognostics ( ($SERA) ) is now available. On August 14, 2026, Sera Prognostics’ board appointed Scott Gleason as Chief Financia...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$2.00	+1.01%	1.04K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SERA	$2.00	+1.0%	1.04K
3
4
5
6

SERA

Get Sera Prognostics, Inc. Data in Excel

Get Sera Prognostics, Inc. Data in Excel